Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Upstream Bio, Inc.NASDAQ: UPB
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables falls 40.5% from a year ago
Net receivables stood at $1.03M at the end of Q1 FY2026, down 40.5% from a year earlier and up 54.8% from the prior quarter. Over 3 fiscal years it compounded at +17.5% a year.
Context
- Net receivables amounted to 0.3% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -40.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 668K USD
- Year-over-year change
- -43.4%
- 3-year CAGR
- +17.5%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 668K | -43.4% |
| FY2024 | 2024-12-31 | 1.18M | +400.0% |
| FY2023 | 2023-12-31 | 236K | -42.7% |
| FY2022 | 2022-12-31 | 412K | — |
Net Receivables vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -40.5% is the 5th highest of 6, against a peer median of +103.7%.
- Net receivables amounts to 0.3% of total assets for UPB, versus a peer median of 0.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $60.69M USD | +182.5% | +158.8% | 12.8% | |
| Mar 2026 | $23.31M USD | -47.6% | +8.9% | 2.2% | |
| Mar 2026 | $9.13M USD | -13.1% | +36.0% | 1.2% | |
| Sep 2026 | €5.98M EUR | +103.7% | +128.3% | 2.0% | |
| Sep 2026 | $2.9M USD | +1150.0% | -82.1% | 0.4% | |
| Mar 2026 | $1.1M USD | — | — | 0.1% | |
UPBUpstream Bio, Inc. | Mar 2026 | $1.03M USD | -40.5% | +17.5% | 0.3% |
| Sep 2026 | $0 USD | — | — | 0.0% | |
| Jun 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding UPB) | — | +103.7% | +36.0% | 0.4% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.